Schizophrenia Research
Volume 115, Issue 2 , Pages 115-120 , December 2009

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

  • Leslie Citrome

      Affiliations

    • Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    • New York University School of Medicine, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. Tel.: +1 845 398 5595; fax: +1 845 398 5483.
  • ,
  • Christopher Reist

      Affiliations

    • University of California, Irvine, CA, USA
  • ,
  • Liisa Palmer

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
  • ,
  • Leslie B. Montejano

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
  • ,
  • Gregory Lenhart

      Affiliations

    • Thomson Reuters, Ann Arbor, MI, USA
  • ,
  • Brian Cuffel

      Affiliations

    • Pfizer Inc., New York, NY, USA
  • ,
  • James Harnett

      Affiliations

    • Pfizer Inc., New York, NY, USA
  • ,
  • Kafi N. Sanders

      Affiliations

    • Pfizer Inc., New York, NY, USA

Received 30 July 2009 ,Revised 12 September 2009 ,Accepted 17 September 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0920-9964(09)00442-3

doi: 10.1016/j.schres.2009.09.023

Schizophrenia Research
Volume 115, Issue 2 , Pages 115-120 , December 2009